Initial Statement of Beneficial Ownership (3)
07 December 2021 - 1:43AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Weiss Amir |
2. Date of Event Requiring Statement (MM/DD/YYYY)
11/24/2021
|
3. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [TEVA]
|
|
(Last)
(First)
(Middle)
C/O 124 DVORA HANEVI'A ST. |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Accounting Officer / |
|
(Street)
TEL AVIV, L3 6944020
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Ordinary Shares (1) | 14391.41 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Restricted Share Units | (2) | (2) | Ordinary Shares (1) | 14258 | (3) | D | |
| Restricted Share Units | (4) | (4) | Ordinary Shares (1) | 9657 | (3) | D | |
| Restricted Share Units | (5) | (5) | Ordinary Shares (1) | 4809 | (3) | D | |
| Restricted Share Units | (6) | (6) | Ordinary Shares (1) | 981 | (3) | D | |
| Stock Options (right to buy) | (7) | 3/2/2028 | Ordinary Shares (1) | 10002 | $19.16 | D | |
| Stock Options (right to buy) | (8) | 3/3/2027 | Ordinary Shares (1) | 7755 | $34.70 | D | |
| Stock Options (right to buy) | (9) | 3/17/2026 | Ordinary Shares (1) | 5003 | $53.50 | D | |
| Stock Options (right to buy) | (10) | 3/12/2025 | Ordinary Shares (1) | 3752 | $60.21 | D | |
| Stock Options (right to buy) | (11) | 3/11/2024 | Ordinary Shares (1) | 1501 | $48.76 | D | |
| Explanation of Responses: |
| (1) | The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| (2) | Restricted share units were granted on March 5, 2021, with 3,564 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 3,566 vesting on March 5, 2025. |
| (3) | Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| (4) | Restricted share units were granted on February 28, 2020 with 3,219 vesting on each of February 28, 2022, February 28, 2023 and February 28, 2024. |
| (5) | Restricted share units were granted on March 4, 2019, with 2,403 vesting on March 4, 2022 and 2,406 vesting on March 4, 2023. |
| (6) | Restricted share units were granted on March 3, 2018 and vest on March 2, 2022. |
| (7) | Stock options were granted on March 3, 2018, with 2,500 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 2,502 vesting on March 2, 2022. |
| (8) | Stock options were granted on March 3, 2017, with 1,938 having vested on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,941 on March 3, 2021. |
| (9) | Stock options were granted on March 17, 2016, with 1,250 having vested on each of March 17, 2017, March 17, 2018 and March 17, 2019 and 1,253 on March 17, 2020. |
| (10) | Stock options were granted on March 12, 2015, with 938 having vested on each of March 12, 2016, March 12, 2017, March 12, 2018 and March 12, 2019. |
| (11) | Stock options were granted on March 12, 2014, with 500 having vested on each of March 12, 2015 and March 12, 2016 and 501 having vested on March 12, 2017. |
Remarks:
Exhibit 24 - Power of Attorney |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Weiss Amir
C/O 124 DVORA HANEVI'A ST.
TEL AVIV, L3 6944020 |
|
| Chief Accounting Officer |
|
Signatures
|
| /s/ Dov Bergwerk as attorney-in-fact for Amir Weiss | | 12/6/2021 |
| **Signature of Reporting Person | Date |
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2023 to Apr 2024
